Bridgehead Programme 2021: Results are in!

Three companies from the D.A.CH region were selected for the EIT Health Bridgehead programme 2021: Munevo, Parsek and Reactive Robotics.

Thirty-five SMEs promoting a wide range of healthcare technologies – from medical imaging to exoskeletons – have been selected to receive support in reaching markets in Europe and beyond as part of EIT Health’s Bridgehead programme. The programme is split into Bridgehead Europe and Bridgehead Global, both of which bring together European health entrepreneurs who want to grow their business beyond their home market with the world’s top incubators and accelerators (Catalysers) to plan how to access new markets quickly and decisively, tap into local networks of partners and clients, access infrastructure and understand new regulatory systems.

Applications were judged by an expert panel based on the innovativeness of their solution, their business model and traction in the home market, and their readiness to expand to other European and global markets. The teams will now be matched with the best Catalysers to suit their requirements at exclusive matchmaking events.

A long time member and participant of the community – Munevo (Germany) – have been selected to receive support through the Bridgehead Global 2021 programme. With Munevo DRIVE, the first wheelchair control using smart glasses that allows user to control the wheelchair hands-free, the Munich-based company aims to empower people with disabilities by using smart and innovative technologies. Participation in Bridgehead Global will empower them to expand their scale-up and take on global markets outside of Europe such as the US, Canada, China, Japan and South Korea by storm.

The Bridgehead Europe 2021 programme provides companies with local knowledge to drive their expansion to other European markets. The selected start-ups are Parsek Information Technologies GmbH (Austria) and Reactive Robotics (Germany). Parsek is using Vitaly Coordinated Care, a comprehensive, patient-centric solution, to offer care teams and patients 24/7 support, personalised to their health needs, while Reactive Robotics has developed VEMO®, a robotic system for intensive care therapy, which provides very early mobilisation for severely ill patients, allowing them to recover faster and free up ICU capacity.

The second round of the Bridgehead 2021 programme is now open for applications. More about the programme here.